Clinical Observation on Shengxuening Treating Anemia in Hemodialysis Patients_West China Medical Journal

Authors：

YANG Yue , FENG Shenggang , BAI Yajun , DU Yanbin

Department of Nephrology, the Second Clinical Medical College, North Sichuan Medical College, Nanchong Central Hospital, Nanchong,Sichuan 637000, P. R. China;

Corresponding author：

Keywords：

口服铁; 生血宁; 血液透析; 促红细胞生成素; 肾性贫血

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】　目的　比较生血宁片和多糖铁复合物胶囊两种口服铁剂在治疗维持性血液透析患者肾性贫血中的治疗效果。　方法　 2008年12月-2010年6月间选择40例维持性血液透析贫血患者，随机分为生血宁片组和多糖铁复合物胶囊组，每组20例，观察期为8周。分别检测两组患者用药前及用药后4、8周时血红蛋白、红细胞压积、血清铁蛋白、转铁蛋白饱和度等指标情况。同时两组患者均使用基因重组人促红细胞生成素，按100~120 U/（kg·周），分两次皮下注射。　结果　治疗前两组指标无明显差异，治疗后两组患者的血红蛋白、红细胞压积、血清铁蛋白以及转铁蛋白饱和度较治疗前均显著上升，且两组患者升高的幅度相比，生血宁组升高的幅度更显著。治疗结束时，两组患者不良反应方面的差异无统计学意义。　结论　两种口服铁剂均能有效地纠正血液透析患者的铁缺乏及贫血状况；生血宁片组的作用更显著，且还具备降低患者促红细胞生成素使用量的作用。
【Abstract】　Objective　 To compare the effect of Shengxuening piece and capsule polysaccharide-iron complex on anemia in hemodialysis patients.　Methods　 A total of 40 patients with anemia in maintenance hemodialysis treated between December 2008 and June 2010 were randomly divided into Shengxuening piece group and capsule polysaccharide-iron complex group; the patients were observed for 8 weeks. Hemoglobin (Hb), hematocrit (Hct), serum ferritin (SF), transferrin saturation (TSAT) and other indicators were detected before treatment four and eight weeks after the treatment. While patients were used recombinant human erythropoietin (EPO) according to 100-120 U/(kg·week), twice subcutaneous injection.　Results　 Before treatment, there was no significant difference between the two groups. Hb, Hct, SF and TSAT increased significantly after treatment in both of the groups and specially in the Shengxuening piece group. After the treatment, the difference in the adverse reaction between the two groups was not significant.　Conclusions　 Both oral iron can effectively correct the hemodialysis patients with iron deficiency and anemia. However, Shengxuening has more significant role and may reduce the use of erythropoietin in patients with hemodialysis.

Citation： YANG Yue,FENG Shenggang,BAI Yajun,DU Yanbin. Clinical Observation on Shengxuening Treating Anemia in Hemodialysis Patients. West China Medical Journal, 2011, 26(11): 1646-1648. doi: Copy

1.	Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries:association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)[J]. Nephrol Dial Transplant, 2004, 19 (1): 121-132.
2.	Portoles J, López-Gómez JM, Aljama P. On behalf of the MAR study group. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR study[J]. Nephrol Dial Transplant, 2007, 22 (2): 500-507.
3.	中华医学会肾脏病学分会. 重组人促红细胞生成素在肾性贫血中合理应用的专家共识[J]. 中国血液净化, 2007, 6(8): 440-443.
4.	袁群生, 郑法雷, 丁峰, 等. 蔗糖铁注射液治疗血液透析患者肾性贫血的多中心研究[J]. 中华肾脏病杂志, 2004, 20(1): 51-54.
5.	汪关煜, 林善琰, 叶朝阳, 等. 多糖铁复合物对肾性贫血肾功衰竭血液透析患者的补铁疗效与安全性观察[J]. 中华内科杂志, 2000, 39(6): 380-383.
6.	Eschbach JW, Egrie GC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin[J]. N Engl J Med, 1987, 316(2): 73-78.
7.	Macdougall IC. Strategies for iron supplementation: Oral versus intravenous[J]. Kidney Int Suppl, 1999, 3(69): s61-s66.
8.	Hamstra RD, Block MH, Schocket al. Intravenous iron dextran in clinical medicine[J]. JAMA, 1980, 243(17): 1726-1731.
9.	刘双信, 史伟, 梁馨苓, 等. 科莫非导致严重过敏反应2例报道[J]. 中国血液净化, 2005, 4(12): 687-688.
10.	Izotova SP. Effect of biologically active substances from treegreens on the physiological state and productivity of mink and rabbits[J]. Chem Abst, 1984, 101(13): 552.
11.	赵堂富, 王素钦, 王秀英, 等. 叶绿素铜钠盐治疗造血障碍性贫血的实验研究[J]. 浙江医学, 1989, 11(4): 193.
12.	魏克民, 裘维焰, 曹宝珍, 等. 叶绿素铜钠盐治疗慢性再生障碍性贫血的临床报道[J]. 医学研究通讯, 1991, 20(4): 24.
13.	刘雪莉, 陈凯, 史红, 等. 铁叶绿酸钠对正常小鼠祖细胞集落和实验性贫血的影响[J]. 中华血液学杂志, 1997, 18(5): 234-236.

1. 　Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries:association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)[J]. Nephrol Dial Transplant, 2004, 19 (1): 121-132.
2. 　Portoles J, López-Gómez JM, Aljama P. On behalf of the MAR study group. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR study[J]. Nephrol Dial Transplant, 2007, 22 (2): 500-507.
3. 　中华医学会肾脏病学分会. 重组人促红细胞生成素在肾性贫血中合理应用的专家共识[J]. 中国血液净化, 2007, 6(8): 440-443.
4. 　袁群生, 郑法雷, 丁峰, 等. 蔗糖铁注射液治疗血液透析患者肾性贫血的多中心研究[J]. 中华肾脏病杂志, 2004, 20(1): 51-54.
5. 　汪关煜, 林善琰, 叶朝阳, 等. 多糖铁复合物对肾性贫血肾功衰竭血液透析患者的补铁疗效与安全性观察[J]. 中华内科杂志, 2000, 39(6): 380-383.
6. 　Eschbach JW, Egrie GC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin[J]. N Engl J Med, 1987, 316(2): 73-78.
7. 　Macdougall IC. Strategies for iron supplementation: Oral versus intravenous[J]. Kidney Int Suppl, 1999, 3(69): s61-s66.
8. 　Hamstra RD, Block MH, Schocket al. Intravenous iron dextran in clinical medicine[J]. JAMA, 1980, 243(17): 1726-1731.
9. 　刘双信, 史伟, 梁馨苓, 等. 科莫非导致严重过敏反应2例报道[J]. 中国血液净化, 2005, 4(12): 687-688.
10. 　Izotova SP. Effect of biologically active substances from treegreens on the physiological state and productivity of mink and rabbits[J]. Chem Abst, 1984, 101(13): 552.
11. 　赵堂富, 王素钦, 王秀英, 等. 叶绿素铜钠盐治疗造血障碍性贫血的实验研究[J]. 浙江医学, 1989, 11(4): 193.
12. 　魏克民, 裘维焰, 曹宝珍, 等. 叶绿素铜钠盐治疗慢性再生障碍性贫血的临床报道[J]. 医学研究通讯, 1991, 20(4): 24.
13. 　刘雪莉, 陈凯, 史红, 等. 铁叶绿酸钠对正常小鼠祖细胞集落和实验性贫血的影响[J]. 中华血液学杂志, 1997, 18(5): 234-236.

West China Medical Journal

Clinical Observation on Shengxuening Treating Anemia in Hemodialysis Patients

Abstract Full text Figures/Tables Video References Cited by

Format

Content